All News
TM83 #ACR23 @RheumNow
45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv
Low Ca, & Phos, ALP 239. Nml Vit D, High PTH.
DEXA: Osteoporosis
FGF23 high
PET/CT showed soft tissue density in nasal septum, few cortical breaks
Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy
Eric Dein ( View Tweet)
Review of rashes in SLE at #ACR23 by Dr. Katherine Shaw, MD
⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment.
@RheumNow https://t.co/u7dwDe9kbt
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens:
patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit
@Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF
David Liew drdavidliew ( View Tweet)
⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment.
🚩Phase II trial of Iberdomide in SLE:
➡️ not associated w/ statistically significant improvement in CLASI-A when including ALL CLE subtypes… https://t.co/LHNqKMALzU https://t.co/K73sXjFTHM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
TM84 #ACR23 @RheumNow
49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis
Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7
Eric Dein ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Watch: Correlation Between Patient and Physicians Assessments in PsA Save
Dr. Antoni Chan interviews Dr. Avin Maroof at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/syG4Ry08vF https://t.co/6g9SpISSIt
Dr. John Cush RheumNow ( View Tweet)
Merging field moving forward - cardio-rheumatology collaboration imp!
Calcium scores in older patients with #RA may be the one take away! Very important to risk predict and mitigate CV events .
Ofcourse history taking still remains key! session 14T118 #ACR23 @RheumNow https://t.co/xoldFlA8EW
Bella Mehta bella_mehta ( View Tweet)
#ACR23 Late-Breaking Abstr#L13 CAR-T is in CT but not RCT yet. Preliminary results from open label (N=3 #SLE of YTB323 (rapcabtagene autocel CD19 directed with preserved T cell stemness) showed favourable CAR T expansion, B cell depletion, early efficacy & safety @RheumNow https://t.co/UQUOfDbFJe
Md Yuzaiful Md Yusof ( View Tweet)
A#2316 #ACR23 @RheumNow
91 SLE pts w COVID v 182 SLE wo COVID ifn
11 SLE/COVID: serious disease
1 death, 7 severe compl
W/in 90d, 15% mild/mod SLE flare 2% severe SLE flare
Flare rate 17.6% higher than no COVID ifn 5% p=0.001
High HV ifn (2% v 1%)
dsDNA/C3 changes not signif diff https://t.co/dxGJNNWuFy
Eric Dein ( View Tweet)
How do we treat #VEXAS - UBA1 mutation
Large multicenter cohort - 110 pts, 99% M
Confirms the benefit of JAKi and tocilizumab
Others not so much
@RheumNow #ACR23 #ACRBest
#abstL03 https://t.co/tRjO31IHiD
Bella Mehta bella_mehta ( View Tweet)
Speaking of real RA drugs for RA-ILD... large multicenter study finds 4 in 5 patients who received ABA had lung stabilization
Nice to see observational data; this would be an amazing opportunity for a pragmatic open label RCT
@RheumNow #ACR23 Abstr 2165 https://t.co/LTpfjTVAur
Mike Putman EBRheum ( View Tweet)
Retrospective database study from Japan of PsA pts:
At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx.
Dc rates lowest for risankizumab
🤔Reasons for switching/discontinuation not mentioned.
#ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE
sheila ( View Tweet)
A#2313 #ACR23 @RheumNow
Utilization of inpt palliative care incr from 2016-2020 in SLE admits from 1.8% 2016 to 2.6% 2020
Pall care use incr: older pt, comorbid index, teaching, large hosps
Lower use: age <35 yo, Black & Hispanic race
Need to address racial disparities in utiliz https://t.co/wQ8NOhm9lK https://t.co/3tJgt4MMDf
Eric Dein ( View Tweet)
Extended-Release Fluticasone Propionate for Injectable Suspension - EP-104IAR
Phase 2 Randomized (1:1), Double-blind, Vehicle-Controlled Trial
318 pts, 57% F, age 64,
Clinically and statistically significant pain relief for 14 weeks compared to vehicle
@RheumNow #ACR23 #abstL04
Bella Mehta bella_mehta ( View Tweet)
Important data re:ADVOCATE study and health related quality of life
Interesting question: is this due to AVA or just simply giving less steroids?
I discuss this on recent podcast: https://t.co/7Jm6ArFpsB
@RheumNow #ACR23 https://t.co/53T1p2Vvyb
Mike Putman EBRheum ( View Tweet)
@EricFMorand SPOCS Study: A#2263 @ACR23
826 pts - 71% high IFN gene sig
Mean SLEDAI-2K lower with low IFNGS
6mo: pts reports 1+ flare 19% high IFNGS, 16% low. Both grps 6.7% LLDAS, but remission 4% low/1.7% high
In 36 mo, <10% LLDAS, <10% remission
@earlyARA @RheumNow https://t.co/z5v4TBVuDG
Eric Dein ( View Tweet)
Post hoc analysis of Ph2 AURA-LV & Ph3 AURORA1
⬆️VOC-treated pts achieved CRR at 1yr vs. control arm (41.0% vs. 21.9%; OR 2.48, p< 0.0001) and PRR at 1yr (OR 2.3, p< 0.0001)
Similar safety profiles
VOC: Additional tx option for LN pts w/ UPCR >/=2g/g
#ACR23 ABST2326 @RheumNow https://t.co/9z1n3s7umU
sheila ( View Tweet)
Very cool meta analysis of IL17i RCTs in PsA
No change in MACE in DMARD naieve pts initiating IL17i across RCTs
A skosh underpowered but worthwhile question & useful data
@RheumNow #ACR23 Abstr2254 https://t.co/ZN8QYgSA1A
Mike Putman EBRheum ( View Tweet)
A#2297 #ACR23 @RheumNow
Baseline IFNα predicts complete response at 2 yrs in LN
HIgh IFNα: incr risk of 2+ renal flare
Increase of 1 unit of IFNα incr risk of 2+ flares by 35% & risk of decr GFR
IFNα cutoff 0.6 for 2+ flare, 1.3 for progr to eGFR <15
AUC 0.6 (weak predictor) https://t.co/FKeDJVNyYj
Eric Dein ( View Tweet)